NDLI: Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Please wait, while we are loading the content...

An Investigation into the Utility of a Multi-compartmental, Dynamic, System of the Upper Gastrointestinal Tract to Support Formulation Development and Establish Bioequivalence of Poorly Soluble Drugs

Conformational Analysis of Therapeutic Proteins by Hydroxyl Radical Protein Footprinting

Pharmacokinetic Evaluation of Intranasally Administered Vinyl Polymer-Coated Lorazepam Microparticles in Rabbits

Design and Characterization of Novel Peptide-Coated Lipid Nanoparticles for Targeting Anti-HIV Drug to CD4 Expressing Cells

Issues and Challenges of Subvisible and Submicron Particulate Analysis in Protein Solutions

The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs

Pharmacokinetics, Lymph Node Uptake, and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab After IV and SC Administration in Mice

Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation

Challenges in Development of Nanoparticle-Based Therapeutics

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

Challenges in Development of Targeted Liposomal Therapeutics

Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents

Role of Metabolism in the Effects of Genistein and Its Phase II Conjugates on the Growth of Human Breast Cell Lines

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding

Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Rat Prefrontal Cortical Dopamine Response to Dual Acting Norepinephrine Reuptake Inhibitor and 5-HT$_{1A}$ Partial Agonist

The AAPS Journal : Volume 14, Issue 1, March 2012

The AAPS Journal : Volume 13

The AAPS Journal : Volume 12

The AAPS Journal : Volume 11

The AAPS Journal : Volume 10

The AAPS Journal : Volume 9

The AAPS Journal : Volume 8

The AAPS Journal : Volume 7

The AAPS Journal : Volume 6

The AAPS Journal : Volume 5

The AAPS Journal : Volume 4

The AAPS Journal : Volume 3

The AAPS Journal : Volume 2

The AAPS Journal : Volume 1

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Content Provider	Springer Nature Link
Author	Zhang, Min Yang, Jin Tao, Lei Li, Lingjun Ma, Pengcheng Fawcett, John Paul
Copyright Year	2012
Abstract	To investigate bioequivalence (BE) testing of an acarbose formulation in healthy Chinese volunteers through the use of recommended and innovative pharmacodynamic (PD) parameters. Following the Food and Drug Administration (FDA) guidance, a randomized, cross-over study of acarbose test (T) and reference (R) (Glucobay®) formulations was performed with a 1-week wash-out period. Preliminary pilot studies showed that the appropriate dose of acarbose was 2 × 50 mg, and the required number of subjects was 40. Serum glucose concentrations after sucrose administration (baseline) and co-administration of sucrose/acarbose on the following day were both determined. Three newly defined PD measures of glucose fluctuation (glucose excursion (GE), GE′ (glucose excursion without the effect of the homeostatic glucose control), and fAUC (degree of fluctuation of serum glucose based on AUC)), the plateau glucose concentration (C$_{ss}$), and time of maximum reduction in glucose concentration (T $_{max}$) were tested in the evaluation. The adequacy of the two parameters recommended by the FDA, ΔC$_{SG,max}$ (maximum reduction in serum glucose concentration) and AUEC$_{(0-4h)}$ (reduction in the AUC$_{(0-4h)}$ of glucose between baseline and acarbose formulation) was also evaluated. The T $_{max}$ values were comparable, and the 90% confidence intervals of the geometric test/reference ratios (T/R) for ΔC$_{SG,max}$, C$_{ss}$, GE, and fAUC were all within 80–125%. The parameter GE′ was slightly outside the limits, and the parameter AUEC$_{(0-4h)}$ could not be computed due to the presence of negative values. In acarbose BE evaluation, while the recommended parameter ΔC$_{SG,max}$ is valuable, the combination of C$_{ss}$ and one of the newly defined glucose fluctuation parameters, GE, GE’, and fAUC is preferable than AUEC$_{(0-4h)}$. The acarbose test formulation can be initially considered to be bioequivalent to Glucobay®.
Starting Page	345
Ending Page	351
Page Count	7
File Format	PDF
ISSN	12341234
Journal	The AAPS Journal
Volume Number	14
Issue Number	2
e-ISSN	15507416
Language	English
Publisher	Springer US
Publisher Date	2012-03-15
Publisher Institution	American Association of Pharmaceutical Scientists
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Pharmacology/Toxicology Biochemistry Pharmacy Biotechnology
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Bioequivalence; Its History, Practice, and Future

Sequential Bioequivalence Approaches for Parallel Designs

The Two Main Goals of Bioequivalence Studies

Pattern Recognition in Pharmacodynamic Data Analysis

Global Harmonization of Comparator Products for Bioequivalence Studies

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Similar Documents

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Bioequivalence; Its History, Practice, and Future

Sequential Bioequivalence Approaches for Parallel Designs

The Two Main Goals of Bioequivalence Studies

Pattern Recognition in Pharmacodynamic Data Analysis

Global Harmonization of Comparator Products for Bioequivalence Studies

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters